Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Kennedy Trust for Rheumatology Research (KTRR) has pledged a minimum of £20M over five years to the Kennedy Institute of Rheumatology at the University of Oxford to support pioneering research into chronic inflammatory disease.

The Kennedy Trust logo
Support from the Kennedy Trust has allowed us to attract exciting new investigators, establish new technologies, and develop an outstanding graduate training programme.
- Professor Fiona Powrie

The support from the KTRR will further the Kennedy Institute’s ambition to harness discovery research and identification of disease pathways for application in the clinic, driving innovative new therapies to benefit patients.

Director of the Institute Professor Fiona Powrie says: “I am delighted that the Kennedy Trust have agreed to extend funding for the Institute for a further five years. With their support we have been able to attract exciting new investigators, establish new technologies, and develop an outstanding graduate training programme.

The renewed, significant funding will allow us to deliver the next phase of our strategy, including capacity building in imaging, microbiome science, informatics, and clinical research to bridge the gap between basic and translational research.”

The new agreement extends the KTRR’s support to the Institute beyond the current agreement which expires in 2021. The funding is awarded through individual grants and subjected to independent review on a regular basis.

Pierre Espinasse, KTRR’s General Manager , says: The quality of the work undertaken at the Institute since its move to Oxford is hugely impressive and the Trust is delighted to be able to reaffirm its longterm commitment to supporting the Institute through this new agreement.

The KTRR funded the Kennedy Institute’s move to Oxford from London in 2013, contributing £22M to the new building located on the University of Oxford’s Old Road Campus, as well as a £5M equipment grant.

The initial agreement also committed £3M support per annum from 2011-2021 enabling the recruitment of new faculty to the Institute, as well as the development of state-of-the-art technology platforms to support key areas of research.

More broadly, the KTRR provides financial support for scientific research into improving ill health caused by rheumatic and related musculoskeletal and inflammatory diseases, particularly in areas that could benefit from long-term coordinated support.

Similar stories

The new Botnar strategy is announced

After a year as the Director of the Botnar Institute for Musculoskeletal Sciences, Professor Jonathan Rees announces a new structure and strategy that will further enhance research and treatment of bone, joint and musculoskeletal conditions.

New global health grant to improve outcomes for patients with hip fracture

Hip fracture patients in Low- and Middle-Income Countries (LMIC) in Asia are set to benefit from a new study that aims to bring best practice programmes to improve quality of life for patients and reduce healthcare costs.

NDORMS welcomes great-granddaughter of former Head of Department

Julia Strubell, great-granddaughter of Professor Josep Trueta, visited NDORMS to find out about his time here and to share her own work with staff and students.

Botnar researchers awarded Fellowships

Arani Vivekanantham has been awarded an NIHR Doctoral Fellowship and a Versus Arthritis Clinical Research Fellowship, and Rachel Kuo was awarded an NIHR Doctoral Research Fellowship.

Better diagnosis and treatment of autoimmune diseases moves a step closer

A study published in Nature outlines a way to find the crucial peptides (protein fragments) that drive autoimmunity, as well as the immune cells that respond to them.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.